How Phagos is Using AI to End Bacterial Disease

Phagos, the sustainable alternative to antibiotics, led by Alexandros Pantalis and Adèle James, has secured 25 million euros Series A funding round co-led by CapAgro, Hoxton Ventures,  CapHorn, and Demeter, with participation from Acurio Ventures, Citizen Capital, Entrepreneurs First, Founders Capital, and Station F.

The funding will support expanding veterinary phage therapy in the field, advancing the next generation of patented AI for phage discovery, and driving global growth across Europe, Asia, and the Americas.

Phagos has created an innovative phage therapy, a natural antibiotic alternative, to combat bacterial diseases. These infections are the world’s second leading cause of human death, a major factor in animal mortality, and contribute to significant food waste. Rising antimicrobial resistance kills millions annually and could cost the global economy up to $100 trillion by 2050, with one in three livestock antibiotics now ineffective, triple the rate of 2000.

Phagos integrates microbiology and AI in a platform that designs highly precise, personalized treatments to tackle bacterial diseases. Its initial focus is animal health, addressing infections like Salmonella and E. coli amid rising antibiotic resistance, with plans to expand into human medicine. Phagos is the first company globally authorized to market personalized phage-based veterinary drugs, a landmark regulatory achievement. Its patented AI analyzes full phage and bacterial genomes to predict interactions, making phage therapy scalable, targeted, and effective.

With a €25 million Series A, Phagos plans to scale its veterinary phage therapy, advance R&D for the next generation of its patented AI platform, and expand its international presence across three continents. Field deployment is already underway with leading industry partners, while the team, currently 90% scientific and technical, will grow to support market launches. The ultimate goal: end bacterial diseases, starting in animal health and eventually extending to humans.